| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fisetin is a plant based flavonoid. Found in strawberries(160ug/g), apples, persimmons, onions, cucumbers, grapes. -Note half-life 3-4hrs - Oral BioAv low (40-50%) Pathways: - induce ROS production in cancer cells, but also known to reduce it. Also a claim Fisetin-Induced Reactive Oxygen Species Production Has No Effect on Apoptosis in RCC cells Also one claim (NAC 10-20mM levels) that NAC enhances ROS/apoptosis - ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓ - Does not appear to lower antioxidants in cancer cells - Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑, - lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : IL-1β↓, TNF-α↓, IL-6↓, - inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, IGF-1↓, uPA↓, VEGF↓, FAK↓, RhoA↓, NF-κB↓, TGF-β↓, ERK↓ - cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓, - inhibits Migration/Invasion : TumCMig↓, TumCI↓, FAK↓, ERK↓, EMT↓, TOP1↓, TET1↓, - inhibits HIF-1α↓, cMyc↓, LDH↓, GRP78↑, - inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, EGFR↓, - inhibits Cancer Stem Cells : CD133↓, β-catenin↓, - Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK↓, ERK↓, JNK, - Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective, - Selectivity: Cancer Cells vs Normal Cells Fisetin effect on Cancer Cells
|
| Source: |
| Type: |
| TRAIL (TNF-related apoptosis-inducing ligand) is a protein that plays a significant role in the regulation of apoptosis, or programmed cell death. It is part of the tumor necrosis factor (TNF) superfamily and has garnered interest in cancer research due to its ability to selectively induce apoptosis in cancer cells while sparing normal cells. TRAIL binds to specific receptors on the surface of cells, known as TRAIL receptors (TRAIL-R1 and TRAIL-R2), which triggers a cascade of signaling events leading to apoptosis. This selective action makes TRAIL a potential therapeutic agent for cancer treatment. TRAIL has been studied as a potential targeted therapy for various cancers, including breast, prostate, and lung cancer. Researchers are exploring ways to enhance its effectiveness, such as combining TRAIL with other treatments (chemotherapy, radiation) or using TRAIL in engineered forms (like TRAIL receptor agonists). |
| 2852- | FIS, | A comprehensive view on the fisetin impact on colorectal cancer in animal models: Focusing on cellular and molecular mechanisms |
| - | Review, | CRC, | NA |
| 2857- | FIS, | A review on the chemotherapeutic potential of fisetin: In vitro evidences |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:78 Target#:313 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid